These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19722264)

  • 21. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.
    Gordon CJ; Muesing MA; Proudfoot AE; Power CA; Moore JP; Trkola A
    J Virol; 1999 Jan; 73(1):684-94. PubMed ID: 9847374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity.
    Vangelista L; Longhi R; Sironi F; Pavone V; Lusso P
    Biochem Biophys Res Commun; 2006 Dec; 351(3):664-8. PubMed ID: 17083916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
    Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
    Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.
    Ham AS; Cost MR; Sassi AB; Dezzutti CS; Rohan LC
    Pharm Res; 2009 Mar; 26(3):502-11. PubMed ID: 19002569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
    Owais M; Arya SK
    J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
    Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
    Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
    J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
    Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity.
    Proudfoot AE; Fritchley S; Borlat F; Shaw JP; Vilbois F; Zwahlen C; Trkola A; Marchant D; Clapham PR; Wells TN
    J Biol Chem; 2001 Apr; 276(14):10620-6. PubMed ID: 11116158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.
    Dudley DM; Wentzel JL; Lalonde MS; Veazey RS; Arts EJ
    J Virol; 2009 May; 83(10):5067-76. PubMed ID: 19279098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
    Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
    Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
    Schols D; Proost P; Struyf S; Wuyts A; De Meester I; Scharpé S; Van Damme J; De Clercq E
    Antiviral Res; 1998 Oct; 39(3):175-87. PubMed ID: 9833958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.
    Lusso P; Vangelista L; Cimbro R; Secchi M; Sironi F; Longhi R; Faiella M; Maglio O; Pavone V
    FASEB J; 2011 Apr; 25(4):1230-43. PubMed ID: 21199933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of some peptides corresponding to the active region of RANTES for chemotaxis and evaluation of their anti-human immunodeficiency virus-1 activity.
    Nishiyama Y; Murakami T; Kurita K; Yamamoto N
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2125-8. PubMed ID: 9433785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.
    Blanpain C; Doranz BJ; Bondue A; Govaerts C; De Leener A; Vassart G; Doms RW; Proudfoot A; Parmentier M
    J Biol Chem; 2003 Feb; 278(7):5179-87. PubMed ID: 12466283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants.
    Czaplewski LG; McKeating J; Craven CJ; Higgins LD; Appay V; Brown A; Dudgeon T; Howard LA; Meyers T; Owen J; Palan SR; Tan P; Wilson G; Woods NR; Heyworth CM; Lord BI; Brotherton D; Christison R; Craig S; Cribbes S; Edwards RM; Evans SJ; Gilbert R; Morgan P; Randle E; Schofield N; Varley PG; Fisher J; Waltho JP; Hunter MG
    J Biol Chem; 1999 Jun; 274(23):16077-84. PubMed ID: 10347159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.